Dyne Therapeutics (NASDAQ:DYN) Earns “Buy” Rating from HC Wainwright

Dyne Therapeutics (NASDAQ:DYN)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $46.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 276.80% from the stock’s previous close.

Several other research analysts have also issued reports on the stock. Chardan Capital reiterated a “buy” rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research report on Monday. Baird R W upgraded Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. Guggenheim reissued a “buy” rating on shares of Dyne Therapeutics in a report on Friday, January 24th. Robert W. Baird assumed coverage on Dyne Therapeutics in a research report on Friday, December 13th. They set an “outperform” rating and a $46.00 price target for the company. Finally, Piper Sandler cut their price target on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. One research analyst has rated the stock with a sell rating, one has given a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $48.85.

Dyne Therapeutics Stock Performance

NASDAQ DYN traded up $0.16 during trading hours on Monday, hitting $12.21. The company had a trading volume of 706,976 shares, compared to its average volume of 1,328,662. The firm has a 50 day simple moving average of $14.58 and a 200 day simple moving average of $25.13. Dyne Therapeutics has a 52 week low of $11.18 and a 52 week high of $47.45. The firm has a market capitalization of $1.38 billion, a price-to-earnings ratio of -3.43 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.04. On average, research analysts forecast that Dyne Therapeutics will post -3.44 earnings per share for the current year.

Insider Buying and Selling at Dyne Therapeutics

In other news, insider Oxana Beskrovnaya sold 2,598 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the completion of the transaction, the insider now owns 199,087 shares in the company, valued at $2,777,263.65. The trade was a 1.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders sold 6,237 shares of company stock worth $77,760. 20.77% of the stock is owned by insiders.

Hedge Funds Weigh In On Dyne Therapeutics

A number of hedge funds have recently bought and sold shares of DYN. FMR LLC increased its position in Dyne Therapeutics by 69.7% during the third quarter. FMR LLC now owns 9,026,697 shares of the company’s stock valued at $324,239,000 after acquiring an additional 3,707,734 shares during the last quarter. Janus Henderson Group PLC lifted its position in shares of Dyne Therapeutics by 8.3% during the 4th quarter. Janus Henderson Group PLC now owns 7,379,309 shares of the company’s stock valued at $173,808,000 after buying an additional 566,146 shares in the last quarter. RTW Investments LP grew its stake in shares of Dyne Therapeutics by 6.8% during the 3rd quarter. RTW Investments LP now owns 6,818,641 shares of the company’s stock valued at $244,926,000 after acquiring an additional 431,503 shares during the period. RA Capital Management L.P. increased its stake in shares of Dyne Therapeutics by 5.5% in the third quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock worth $229,211,000 after purchasing an additional 331,940 shares in the last quarter. Finally, State Street Corp raised its holdings in Dyne Therapeutics by 13.8% during the third quarter. State Street Corp now owns 3,641,859 shares of the company’s stock valued at $130,816,000 after acquiring an additional 440,890 shares during the period. Hedge funds and other institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.